Sign In
Buy AXSM
$233.49
+11.33 (+5.10%)
At Close: Jun 03, 2026
Axsome Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update
07:00am, Monday, 23'rd Feb 2026
NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
GSA Capital Partners LLP Makes New Investment in Axsome Therapeutics, Inc. $AXSM
05:52am, Monday, 23'rd Feb 2026
GSA Capital Partners LLP purchased a new stake in Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to the company in its most recent disclosure with the Securities and
Got $10,000? Axsome Therapeutics Could Be a Mental‑Health Moonshot by 2036
01:00am, Sunday, 22'nd Feb 2026
Axsome Therapeutics' lineup and late-stage pipeline could help drive strong sales growth for a while. The biotech won't run into patent cliffs in the near future, either.
AI, Clean Energy & Health Stocks: The Big Winners in a Multipolar 2026
03:01pm, Friday, 20'th Feb 2026
NVIDIA, Albemarle and Axsome Therapeutics emerge as standout plays as AI, clean energy and healthcare draw massive capital in a split 2026 market.
Axsome Therapeutics, Inc. (NASDAQ:AXSM) Receives Consensus Rating of “Moderate Buy” from Analysts
01:38am, Thursday, 19'th Feb 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the eighteen analysts that are currently covering the company, MarketBeat Rati
Axsome Therapeutics Settles SUNOSI® (solriamfetol) Patent Litigation with Alkem Laboratories Ltd.
07:00am, Tuesday, 17'th Feb 2026
NEW YORK, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM) (Axsome), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders,
Axsome Therapeutics (AXSM) Expected to Beat Earnings Estimates: Should You Buy?
11:00am, Monday, 16'th Feb 2026
Axsome (AXSM) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Buy Axsome Therapeutics Stock Before Feb. 23?
09:00am, Thursday, 05'th Feb 2026
The healthcare company is set to release its fourth-quarter results later this month.
1 High-Flying Stock With More Upside Ahead
11:45am, Tuesday, 03'rd Feb 2026
Axsome Therapeutics' current product lineup has been driving solid revenue growth. The biotech should earn several approvals or label expansions in the next few years.
Axsome Therapeutics to Report Fourth Quarter and Full Year 2025 Financial Results on February 23
07:00am, Tuesday, 27'th Jan 2026
NEW YORK, Jan. 27, 2026 (GLOBE NEWSWIRE) -- Axsome Therapeutics, Inc. (NASDAQ: AXSM), a biopharmaceutical company leading a new era in the treatment of central nervous system (CNS) disorders, today an
Auvelity Continues to Aid AXSM's Top Line: More Upside in 2026?
11:15am, Monday, 26'th Jan 2026
Axsome's Auvelity delivered robust 2025 sales growth. A pending FDA decision in 2026 could unlock a broader market and drive sales further.
Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM
05:48am, Monday, 26'th Jan 2026
Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ: AXSM) by 30.7% during the undefined quarter, according to the company in its most recent
Cabot Wealth Management Inc. Buys Shares of 5,560 Axsome Therapeutics, Inc. $AXSM
03:50am, Monday, 26'th Jan 2026
Cabot Wealth Management Inc. purchased a new stake in shares of Axsome Therapeutics, Inc. (NASDAQ: AXSM) during the undefined quarter, according to its most recent 13F filing with the Securities and E
Ari Maizel Sells 7,500 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
04:58am, Sunday, 25'th Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) insider Ari Maizel sold 7,500 shares of the stock in a transaction that occurred on Wednesday, January 21st. The stock was sold at an average
Nick Pizzie Sells 12,000 Shares of Axsome Therapeutics (NASDAQ:AXSM) Stock
04:02am, Sunday, 25'th Jan 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM - Get Free Report) CFO Nick Pizzie sold 12,000 shares of the company's stock in a transaction on Thursday, January 22nd. The shares were sold at an average pric
